Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
Сульфасалазин и 5-аминосалицилат Препараты 5-АСК обладают очень слабой иммуносупрессивной активностью. Нет сообщений о том, что эти препараты связаны с повышенным риском инфицирования, а исследования, оценивающие профиль безопасности 5-АСК, не демонстрируют повышенного риска серьезных или оппортунистических инфекций. Лечение 5-АСК следует продолжать, не беспокоясь о повышенном риске заражения или развития тяжелой формы COVID-19 . Если пациент находится в контакте с больным COVID-19 или у него развивается COVID-19, лечение 5-АСК следует продолжить.
"It was an ordinary day, a cold morning. I was sleeping after a night shift and woke up from the fact that massive shelling had begun. A tank unit of 16 tanks approached us. Our armored personnel carrier was shot down before my eyes and I ran to help pull the guys out, but did not I ran a little, there were about seven meters left, I could hear the whistle of shells, explosions and darkness ... I rubbed my eyes from the ground and saw that there was a bare bone in the place of the arm, I thought that I should see what was happening with my legs, if I could move. "I thought that I would die, but I was lying, I realized that I would not die for a long time, that I would live and I had to do something, and I put on a tourniquet," the military man says.
Analyzing the subjective assessment of health by student youth (under the age of 25), we found the following: the vast majority of respondents, regardless of gender, rated their own health as "good" and "very good". Almost half of the guys and every fifth girl noted the criterion for assessing "excellent" health. About 2% of boys and 3% of girls noted that they have “excellent” health. The criteria for assessing the health of "mediocre" and "poor" for the children practically did not differ. Thus, “mediocre” health was observed in 15% of boys and 14% of girls; "bad" - 2% of boys and 2% of girls.
5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием